Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867357 | 0.86 | KMT2A (0.40) | OPRD1OPRM1KMT2AALDH1A1 | |
| SCHEMBL4866159 | 0.77 | OPRD1 (0.41) | OPRD1MAPTKMT2ASLC6A4SLC6A2 | |
| SCHEMBL4558669 | 0.67 | CHRM3 (0.41) | OPRD1MAPTSIGMAR1KMT2AALDH1A1 | |
| SCHEMBL4866544 | 0.67 | CHRM3 (0.34) | OPRM1MAPTSIGMAR1KMT2AALDH1A1 | |
| SCHEMBL4957427 | 0.67 | KMT2A (0.39) | OPRD1OPRM1OPRK1MAPTKMT2A | |
| SCHEMBL4899599 | 0.66 | CHRM3 (0.40) | OPRD1MAPTSIGMAR1KMT2AALDH1A1 | |
| SCHEMBL2170767 | 0.66 | MAPT (0.37) | OPRD1OPRM1OPRK1MAPTKMT2A | |
| SCHEMBL4559545 | 0.66 | SIGMAR1 (0.44) | OPRD1MAPTSIGMAR1KMT2AALDH1A1 | |
| SCHEMBL4559549 | 0.65 | KMT2A (0.41) | OPRD1MAPTSIGMAR1KMT2AALDH1A1 | |
| SCHEMBL9989678 | 0.65 | KMT2A (0.43) | OPRD1OPRM1SIGMAR1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-8772336-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | AXYS PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8318748-B2 | Cathepsin cysteine protease inhibitors | Merck, Sharp & Dohme Corp. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | CTSB, CTSS, CTSZ | OPRD1 3487/4885OPRM1 4786/4885OPRK1 3837/4885 |
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | OPRD1 3955/4885OPRM1 4784/4885OPRK1 3567/4885 |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | CTSE, CTSL, CTSK | OPRD1 1848/4885OPRM1 2615/4885OPRK1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.